Altfest L J & Co. Inc. Raises Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Altfest L J & Co. Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 116.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,573 shares of the medical research company’s stock after purchasing an additional 847 shares during the quarter. Altfest L J & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $835,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 104,536.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after acquiring an additional 8,347,260 shares during the period. Providence Capital Advisors LLC lifted its holdings in Thermo Fisher Scientific by 61,754.7% in the first quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after acquiring an additional 5,832,730 shares during the period. Norges Bank purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $3,105,677,000. Morgan Stanley lifted its stake in shares of Thermo Fisher Scientific by 17.7% in the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after purchasing an additional 1,764,312 shares during the period. Finally, Loomis Sayles & Co. L P grew its position in Thermo Fisher Scientific by 17,046.7% during the third quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock valued at $492,803,000 after buying an additional 967,913 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.0 %

NYSE:TMO traded up $0.19 during trading hours on Thursday, hitting $579.56. The company had a trading volume of 349,366 shares, compared to its average volume of 1,606,351. The company has a 50-day moving average of $564.32 and a 200 day moving average of $519.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The company has a market cap of $220.99 billion, a P/E ratio of 37.50, a P/E/G ratio of 2.39 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. Thermo Fisher Scientific’s revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $5.40 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 target price on the stock. Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. HSBC assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 18th. They issued a “buy” rating and a $610.00 price target on the stock. Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Robert W. Baird restated an “outperform” rating and set a $670.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $599.00.

Insider Buying and Selling

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.